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Abstract
Objectives: The aim of this study was to assess the biological rationale for the use of
platelet-rich plasma (PRP) by evaluating the effect of different concentrations of PRP on
osteoblasts (OB) and fibroblasts (FB) function in vitro.
Material and methods: PRP was obtained from volunteer donors using standard protocols.
Primary human cultures of oral FBs and OBs were exposed to both activated and non-
activated plasma as well as various concentrations of PRP (2.5  , 3.5  and max (4.2–
5.5  )). Cell proliferation was evaluated after 24 and 72h using an MTT proliferation assay.
Production of osteocalcin (OCN), osteoprotegerin (OPG) and transforming growth factor b1
(TGF-b1) was evaluated in OB after 24 and 72h. Statistical analysis was performed using
one-way ANOVA.
Results: PRP-stimulated cell proliferation in both OBs and FBs. The effect of different PRP
concentrations on cell proliferation was most notable at 72h. The maximum effect was
achieved with a concentration of 2.5  , with higher concentrations resulting in a reduction
of cell proliferation. Upregulation of OCN levels and downregulation of OPG levels were
noted with increasing PRP concentrations at both 24 and 72h. TGF-b1 levels were
stimulated by increasing concentrations of PRP, with the increased levels being maintained
at 72h.
Conclusions: PRP preparations exert a dose-specific effect on oral FBs and OBs. Optimal
results were observed at a platelet concentration of 2.5  , which was approximately
half of the maximal concentrate that could be obtained. Increased concentrations
resulted in a reduction in proliferation and a suboptimal effect on OB function. Hence,
different PRP concentrations may have an impact on the results that can be obtained
in vivo.
At a cellular level, wound healing and
regeneration involves a complex cascade
of events, including cell proliferation and
differentiation. These processes are known
to be modulated by growth factors. Conse-
quently, over the past two decades, the
potential use of growth factors in bone
and periodontal regeneration has been in-
vestigated and in principle viability has
been demonstrated (Cochran & Wozney
1999).
One way of delivering concentrated
amounts of growth factors to the wound
site is via the use of platelet-rich plasma
(PRP). PRP is a concentration of human
platelets in a small volume of plasma. It
contains concentrated amounts of the se-
ven growth factors shown to be activelyCopyrightr Blackwell Munksgaard 2005
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secreted by platelets – the three isomers of
platelet-derived growth factor (PDGF-AA,
PDGF-BB and PDGF-AB), two forms of
transforming growth factor b (TGF-b1 and
TGF-b2), vascular endothelial growth fac-
tor and epithelial growth factor. Initially, it
was reported that PRP has a positive effect
on bone regeneration in mandibular defect
reconstruction (Marx et al. 1998). Subse-
quently, the use of PRP has been investi-
gated in several studies, with some
reporting success in promoting regenera-
tion (Kassolis et al. 2000; Mazor et al.
2004), while others found no additional
benefit (Aghaloo et al. 2002; Froum et al.
2002). Therefore, the clinical usefulness of
PRP remains controversial (Sanchez et al.
2003; Tozum & Demiralp 2003; Marx
2004). In particular, the methods of pre-
paration of PRP and consequently, the
concentration of growth factors that are
achieved are variables that may explain
the different clinical results that are
obtained.
Although individual, purified growth
factors have been extensively studied in
vitro (for a review, see Cochran & Wozney
1999) prior to use in vivo, PRP has only
recently started to be assessed in a similar
manner. However, studies investigating
the effect of PRP on cell function in vitro
have utilized a wide variety of cell types
and have obtained conflicting results (Liu
et al. 2002; Lucarelli et al. 2003; Gruber
et al. 2004; Kilian et al. 2004; Soffer et al.
2004; Kanno et al. 2005). In particular, it is
still uncertain which concentrations of
PRP are optimal in promoting enhanced
wound healing and regeneration. It is
assumed that PRP would act in a similar
manner to individual growth factors and
that preparations containing maximal con-
centration of growth factors are ideal. How-
ever, there is little evidence to support this
assumption, which may be flawed on the
basis that PRP is a combination of different
growth factors, each of which exerts a
unique influence on the complex cascade
of events that occur during wound healing
and regeneration. The aim of this study
was to assess the effect of different concen-
trations of PRP on the proliferation and
differentiation of human oral fibroblasts
(FB) and osteoblasts (OB) in vitro. A con-
trolled in vitro system was used in order to
provide data that will assist in the future
design of clinical studies utilizing PRP.
Material and methods
PRP preparation
PRP was prepared from venous blood ob-
tained from three volunteer donors (age
range 24–29 years) at the Department of
Hematology, University of Pisa by a stan-
dard aphaeresis procedure using an MCSþ
(Haemonetics, Briantree, MA, USA) device
and acid citric dextrose (ACD-A; 22 g/l
sodium citrate, 24.5 g/l glucose monohy-
drate and 8 g/l citric acid monohydrate)
at a ratio of 1 : 10. The donors’ platelet
counts in venous blood were 185,000–
268,000platelets/ml. The platelets were
automatically leucodepleted by negative-
charged pall filter.
Different platelet concentrations were
obtained relative to the concentrated plate-
let count (range 800,000–1,375,000 plate-
lets/ml, representing an increase of 420–
550% over the baseline venous count) by
diluting with Dulbecco’s modification of
Eagle’s medium (DMEM) (Gibco Inc.,
Rockville, MD, USA). Platelet concentra-
tions of 250% (PRP-2.5  ), 350% (PRP-
3.5  ) and 420–550% (PRP-max) of the
normal venous blood counts were
achieved.
Cell culture
Human OB and gingival FB were obtained
from a 57-years-old woman undergoing
molar tooth extraction.
OBs cells were obtained according to the
technique described by Mailhot & Borke
(1998). Briefly, bone chips obtained during
the extraction were collected in serum-free
DMEM supplemented with penicillin/
streptomycin (100U/ml) (Sigma, St Louis,
MO, USA) and adjusted to pH 7.4. After
30min of digestion using 1mg/ml of col-
lagenase (Boehringer Mannheim, Indiana-
polis, IN, USA) at 371C, the supernatant
was extracted and transferred to another
centrifuge tube. This treatment was re-
peated six times, with the first two frac-
tions being discarded. The subsequent
fractions of released cells, together with
the remaining bone tissue, were pooled,
centrifuged and plated onto six-well culture
dishes.
Human gingival FBs were obtained ac-
cording to the technique described by Spec-
chia et al. (2001). Briefly, gingival tissue
samples were minced into small pieces
using microdissection scissors and washed
with serum-free DMEM. The gingival tis-
sue was then digested in serum-free med-
ium containing 1mg/ml of collagenase at
371C in 5% CO2 for 80min. The super-
natant was removed and the remaining
gingival tissue was placed in six-well cul-
ture dishes, allowing cells to migrate from
the explants.
Following explantation, both OB and FB
cultures were maintained in DMEM sup-
plemented with 10% feotal bovine serum
and 100U/ml of penicillin—streptomycin,
and incubated in a humidified atmosphere
at 371C with 5% CO2 until they formed
monolayers. Cells were passaged when
confluence was reached and utilized fol-
lowing the third passage.
Cell proliferation
Human OBs and FBs (1000 cells/well)
were seeded subconfluently in 96-well
plates in 100ml of serum-free DMEM and
allowed to attach overnight. Subsequently,
the cells were grown for 24 and 72h
following the addition of 50 ml of seven
different preparations: (i) DMEM only (ne-
gative control), (ii) DMEMþ 10% FCS (po-
sitive control), (iii) non-activated plasma
(NAP), (iv) activated plasma (PRP-1  ), (v)
PRP-2.5  , (vi) PRP-3.5  and (vii) PRP-
max (4.5–5.5  ).
PRP was activated before insertion into
the wells by adding 1ml of each prepara-
tion to 50 ml of calcium gluconate and 50 ml
autologous thrombin. Thereafter, 50 ml of
each preparation was added to six different
wells. The experiment was repeated for
each of the three PRP donors.
Cell proliferation analysis was performed
with the MTTt cell proliferation kit
(Roche GmbH, Mannheim, Germany), a
colorimetric assay thatmeasures the reduc-
tion of a tetrazolium component (MTT)
into an insoluble formazan product by the
mitochondria of viable cells. The amount
of colour produced is directly proportional
to the number of viable cells.
OB function
OBs were plated in 96-well plates as out-
lined above and were stimulated with
NAP, activated plasma (PRP-1), PRP-
2.5  , PRP-3.5  and PRP-max. Follow-
ing stimulation for 24 and 72h, 70 ml of
media was removed from the wells. The
quantities of osteocalcin (OCN), osteopro-
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tegerin (OPG) and TGF-b1 were then
assessed.
OCN was measured using a competitive
immunoassay kit (Metrat Osteocalcin,
Quidel Corporation, Santa Clara, CA,
USA) according to the manufacturer’s pro-
tocol and as described by Zhang et al.
(2003). The antibody is conformationally
dependent and recognizes only intact (de
novo) OCN and not degraded fragments.
OPG assessment was performed using a
highly sensitive sandwich enzyme-linked
immunosorbent assay (ELISA, Biomedica
Gruppe, Wien, Austria) according to the
manufacturer’s protocol and as previously
described (Buzi et al. 2004). The assay
detects both monomeric and dimeric forms
of OPG, including OPG bound to its li-
gand. TGF-b1 levels were also determined
by a sandwich ELISA method (BioSource
International, Camarillo, CA, USA) ac-
cording to the manufacturer’s instructions.
Statistical analysis
One-way ANOVA test was used to assess
the effect of the various PRP preparations
on OB and FB proliferation, as well as
production of OCN, OPG and TGF-b1 by
OBs. In order to identify differences be-
tween the various treatments, post hoc
analysis was carried out using the Fisher
LSD test and the Bonferroni test. Statistical
differences between groups were accepted
for P-values lower than 0.05.
Results
Cell proliferation
OBs
The effects of PRP concentrations on OBs
at 24 and 72h are shown in Figs 1a and b,
respectively. After 24h, NAP did not in-
duce a statistically significant proliferative
response compared with the negative con-
trol. However, both activated plasma (PRP-
1  ) and PRP-2.5  stimulated OB pro-
liferation compared with NAP (Po0.05).
The maximum OB proliferation was ob-
tained with activated plasma (PRP-1  ),
with increasing concentrations of PRP re-
sulting in decreased proliferation. The dif-
ference between PRP-1  and PRP-max
was statistically significant (Po0.05).
At 72h, there was a statistically signifi-
cant increase in OB proliferation by all
preparations containing plasma (includ-
ing NAP) compared with the negative con-
trol. Furthermore, PRP-1  (Po0.001),
PRP-2.5  (Po0.001) and PRP-3.5 
(Po0.001) induced a statistically signifi-
cant increase in proliferation compared
with the NAP. The highest cell prolifera-
tion was obtained with PRP-2.5  , with a
70% increase in cell numbers at this con-
centration compared with the negative
control. Furthermore, the increase of pro-
liferation induced by PRP-2.5  was sta-
tistically higher than PRP-max (Po0.001).
FBs
The effects of PRP concentrations on FBs
at 24 and 72h are shown in Figs 2a and b,
respectively.
After 24h, there was no statistical
difference in viable cell numbers between
NAP and the negative control. Compared
with NAP, statistically significant in-
duction of proliferation was noted
with PRP-1  (Po0.001) and PRP-2.5 
(Po0.05). Maximum FBs proliferation
was obtained with PRP-1  (Fig. 2a),
but no statistical differences were noted
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Fig. 1. (a, b) Box and whiskers plots showing the effect of PRP concentrations on osteoblasts at 24 and 72h.
Boxes refer to the 25th (bottom) and 75th (up) percentiles and the median is the horizontal line inside. Open
circles represent outliers. Significantmultiple comparison differenceswere observed between groups (nPo0.05,
nnPo0.01, nnnPo0.001, Fisher LSD adjustment). Only differences between various platelet-rich plasma (PRP)
concentration and non-activated plasma group are reported. Significant differences between positive (PC) and
negative controls (NC) and the plasma/PRP groups are not reported in the graphs and explained in the text.
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between the various concentrations of PRP
(Fig. 2a).
At 72h, there was a significant increase
in FB cell proliferation in NAP compared
with the negative control (Po0.001).
Furthermore, both PRP-1  (Po0.05)
and PRP-2.5  (Po0.001) demonstrated
statistically significant increases in prolif-
eration compared with the NAP. The high-
est induction in proliferation was noted
with PRP-2.5  with an 85% increase in
viable cell numbers compared with the
negative control. However, no statistical
significantly differences were detected be-
tween the various PRP concentrations.
OB function
Functional aspects of OB activity were
assessed by measuring the production of
three secreted proteins that are important
to the regulatory role of OBs during regen-
eration – the extracellular matrix molecule
OCN, the soluble receptor osteoprotegrin
and the growth factor TGF-b1. OB function
was evaluated following the addition of
non-activated PRP, PRP-1  , PRP-2.5  ,
PRP-3.5  and PRP-max.
The effect of the different concentrations
of PRP on OCN and OPG levels is shown
in Figs 3 and 4, respectively. At 24h, there
was a statistically significant (Po0.05)
increase in OCN levels following treat-
ment with PRP-max compared with both
inactivated and activated (PRP-1  )
plasma. Following 72h of exposure to the
various concentrations of PRP, statistically
significant upregulation of OCN was ob-
served with PRP-3.5  and PRP-max
compared with NAP, PRP-1  and PRP-
2.5  (Po0.05). There was a generalized
decrease in OCN levels between 24 and
72h, especially following exposure to
the lower concentrations of PRP (Figs 3a
and b).
OPG levels were downregulated follow-
ing exposure to increasing concentrations
of PRP. At 24h, both PRP-max and PRP-
3.5  induced statistically significant
(Po0.05) decreases in OPG levels com-
pared with non-activated and activated
plasma (PRP-1). At 72h, there was a sta-
tistically significant decrease in OPG le-
vels for PRP-max compared with NAP,
PRP-1  and PRP-2.5  (Po0.05). Inter-
estingly, a large increase in OPG levels was
noted between 24 and 72h (Figs 4a and b).
TGF-b1 levels were not greatly affected
following exposure to the various PRP
concentrations (Fig. 5). There was a general
trend towards increased levels of TGF-b1
following exposure to increased concentra-
tions of PRP. Indeed, there was a statisti-
cally significant increase of TGF-b1 levels
in PRP-max compared with PRP-1  at
24h. No statistical differences between the
groups were noted following 72h.
Discussion
In recent years, the use of PRP has gained
considerable popularity for the purpose of
delivering growth factors to the wound-
healing site in order to promote regenera-
tion. Because PRP is prepared in the dental
surgery from autogenous blood, it confers
several advantages over other products and
techniques, most notably in terms of
simplicity, safety and cost-effectiveness.
However, because of these favourable
characteristics, the use of PRP has been
perceived as a therapy, which, at the very
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Fig. 2. (a, b) Box and whiskers plots showing the effect of platelet-rich plasma (PRP) concentrations on
fibroblasts at 24 and 72h. Significant multiple comparison differences were observed between groups
(nPo0.05, nnPo0.01, nnnPo0.001, Fisher LSD adjustment). Only differences between various PRP concen-
trations and non-activated plasma group are reported. Positive (PC) and negative (NC) control that showed the
significant differences are reported in the text.
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worst, will not negatively affect the clinical
outcome. Consequently, the use of PRP
has not been placed under as much scru-
tiny as other techniques, especially those
utilizing exogenous growth factors. Al-
though the biological rationale for the use
of PRP is theoretically sound, the precise
methodology that will result in the optimal
benefit from this therapy is yet to be
elucidated. In particular, the precise PRP
concentrations that would be ideal are yet
to be determined. This study was designed
to test the effect of varying the concentra-
tions of PRP on the function of primary
human OBs and FBs during the early
phases of the healing process (days 1–3).
This study investigated the effect of PRP
on the proliferation of OBs and FBs, the
two cell types critical for wound healing of
soft tissues and bone. Furthermore, as PRP
has been used extensively for bone regen-
eration, we investigated the effect of differ-
ent PRP concentrations on osteoblast
function. Although a variety of different
animal- and human-derived cell lines have
been used to investigate responses to PRP
in vitro, this study utilized primary OBs
and FBs derived from oral sites, as these
cells would normally be involved in wound
healing in the oral region.
The findings of this study indicate that
PRP stimulates OB and FB proliferation,
which is consistent with findings reported
by a number of other studies investigating
the effect of PRP on the proliferation of a
variety of cell types, including AG1518
FBs (Liu et al. 2002), rat calvarial bone
cells (Soffer et al. 2004), human mesench-
ymal progenitor cells (Lucarelli et al. 2003;
Gruber et al. 2004), endothelial cells
(Kilian et al. 2004), primary periodontal
ligament cells (Okuda et al. 2003), com-
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Fig. 3. (a, b) Effect of the different concentrations of platelet-rich plasma
(PRP) on osteocalcin (OCN) levels produced by osteoblasts at 24 and 72h,
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mercially available human gingival FB
(Gin-1), OB MG63 and rat OB UMR106
cell lines (Okuda et al. 2003) and human
osteosarcoma cell lines HOS and SaOS-2
(Kanno et al. 2005). Indeed, some recent
studies have shown a PRP dose-dependent
proliferation increase in the cells under
investigation (Lucarelli et al. 2003; Gruber
et al. 2004; Kilian et al. 2004; Soffer et al.
2004), with increasing PRP concentrations
resulting in enhanced cell proliferation.
However, these studies varied greatly in
the methodology that was utilized, includ-
ing length of observation, method of PRP
preparation, composition of the PRP pre-
parations (co-incubated with 1–2% FCS)
and the type of cells used (mesenchymal
stem cells, rat OBs).
In the present study, although the effect
of PRP on proliferation was dose depen-
dent, increasing PRP concentrations did
not result in increasing proliferation. As
cell proliferation is a critical event during
early wound healing, it appears that the
maximal PRP concentrations used in this
study, which varied between a 4.2- and
5.5-fold increase over the original platelet
concentration, may not provide the opti-
mal environment for the promotion of
wound healing. Our results correlated
with the findings of Liu et al. (2002),
who investigated the effect of different
platelet concentrations on FBs. They pre-
pared maximally concentrated platelet pre-
parations and diluted them in media to
final concentrations of 8.8%, 17.5% and
35%. They found that superior prolifera-
tion was obtained with the 8.8% and
17.5% preparations compared with the
35% concentration. Correlation can be
made with our study where the PRP-max
proliferation was obtained by adding 50 ml
of the maximal platelet concentrate to
100ml of media, giving a final concentra-
tion of 33%. This concentration results in
inferior proliferation compared with PRP-
2.5  , which is approximately half of the
PRP-max concentration (i.e. 16.5%). Liu
et al. (2002) suggested that the inferior
proliferation was pH dependent, and that
high PRP concentrations resulted in pH
changes that negatively affected prolifer-
ation.
Aside from proliferation, this study also
examined OB function by assessing the
production of OCN, OPG and TGF-b1 by
OBs following exposure to different PRP
concentrations. OCN is a bone-specific
non-collagenous matrix protein that regu-
lates mineralization (Boskey et al. 1998)
and plays a significant role in the differen-
tiation of osteoclast progenitors (Webber
et al. 1990) and therefore enhances bone
remodelling activity. OPG is a member of
the TNF receptor superfamily and is un-
ique in that it lacks transmembrane and
cytoplasmic domains and is secreted by
osteoblastic cells as a soluble protein (Sim-
onet et al. 1997). OPG acts as a decoy
receptor by binding the receptor activator
of nuclear factors kB (RANKL) and prevent-
ing RANKL-induced osteoclastic bone re-
sorption (Lacey et al. 1998). TGF-b1 is a
growth factor that promotes osteogenic
differentiation and osteoclastogenesis (Yan
et al. 2001; Koseki et al. 2002; Wildemann
et al. 2004). It has been suggested that the
effect of PRPs on cells is cell type-specific
and mediated via TGF-b1 (Okuda et al.
2003). Interestingly, there have been differ-
ent reports regarding the osteogenic differ-
entiation potential of PRPs, with some
studies indicating stimulation (Kilian et al.
2004) and others showing inhibition (Ar-
pornmaeklong et al. 2004; Gruber et al.
2004).
In our study, increasing PRP concentra-
tions led to increased production of OCN
and decreased production of OPG by
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the OBs. The increase in OCN activity
suggests that the OBs are undergoing dif-
ferentiation. Additionally, the decrease
in OPG and the increase in OCN are indi-
cative of increased osteoclastic activity.
Furthermore, it was noted that TGF-b1
was increased in PRP-max, which corre-
lates with the OCN and OPG findings and
suggests that, during the early phases of
healing, PRP-max stimulates osteoclasto-
genesis and OB differentiation.
Although both proliferation and differen-
tiation are important for bone regeneration,
these two processes cannot occur in the cell
at the same time. Our findings indicate
that high concentrations of platelets may
lead to an increase in OB differentiation at
the cost of proliferation. This may lead to
suboptimal clinical results because cell
proliferation is essential in the early phases
of regenerative wound healing and has to
occur before differentiation is initiated. Our
findings are supported by Weibrich et al.
(2004), who histologically evaluated the
in vivo effect of different concentrations of
platelets on the bone regeneration around
implants placed in femurs of rabbits. They
found that the use of platelet concentrate
had a positive effect on bone regeneration
only within an ‘intermediate’ concentra-
tion range. Indeed, the use of highly con-
centrated platelet preparations (6–11 times
the basal platelet count) appeared to have
an inhibitory effect on healing,
In summary, it can be concluded that
PRP is an effective stimulator of OB and
FB proliferation, as well as OB function.
Furthermore, these data indicate that a
moderate increase of the normal platelet
count provided the most optimal environ-
ment for wound healing through a more
ideal balance between proliferation and
differentiation. These findings suggest
that future clinical studies should be de-
signed with the understanding that PRP
concentrations may affect clinical out-
come.
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